Virtual Tour
Media
NEWS
Contact Us
Patients
Neurology & Ophthalmology
CinnoVex
ReciGen
CinnoTec
Xacrel
TYALIa
Cinnomer
Oncology & Hematology
PegaGen
CinnaPoietin
ZakAria
Ablyze
CinnaStim
Pectuna
Xtramab
KidiPeg
Endocrinology & infertility
Cinnal-f
CinnaFact
CinnaTropin
Melitide
CinnoPar
Maciza
Herozyme
Lixafert
Autoimmune & Immunology & Enzymes
Zerafil
SpikoGen
Eldixia
CinnoRA
Healthcare Professionals
Neurology & Ophthalmology
CinnoVex
ReciGen
Cinnomer
Xacrel
TYALIa
CinnoTec
Oncology & Hematology
PegaGen
CinnaPoietin
KidiPeg
ZakAria
Ablyze
CinnaStim
Pectuna
Endocrinology & infertility
Cinnal-f
CinnaTropin
Herozyme
CinnaFact
CinnoPar
Lixafert
Melitide
Autoimmune & Immunology
CinnoRA
Zerafil
SpikoGen
Capabilities
Our Technology
Business Development
Our Manufacturing Sites
Research and Development
About Us
Presidential Note
About CinnaGen
Mission Statement
Policy
Management Team
Search
Virtual Tour
Media
NEWS
Contact Us
News
2020
Researchers announced safety and effectiveness of ReciGen (interferon beta-1a 44 mcg manufactured by CinnaGen Co.) on COVID-19 patients
20June 2020
Happy New Year
01Jan 2020
Home
News: 2020
Back top Top
